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Abstract 
Objectives 
The objectives of this analysis were to investigate predictors of progression, 
stabilisation or improvement in eGFR after development of chronic renal impairment 
(CRI) in HIV-positive individuals.  
Design  
Prospective observational study. 
Methods 
D:A:D study participants progressing to CRI defined as confirmed, >3 months apart, 
eGFR<70 mL/min/1.73m2 were included in  the analysis. The median of all eGFRs 
measured 24-36 months post-CRI was compared to the median eGFR defining CRI, 
and changes were grouped into: improvement (>+10 mL/min/1.73m2), stabilisation   
(-10 to +10 mL/min/1.73m2) and progression (<-10 mL/min/1.73m2). Adjusted 
polynomial regression models assessed odds of better eGFR outcomes after CRI, 
assuming eGFR improvement is better than stabilisation which in turn is better than 
progression. 
Results 
Of 2006 individuals developing CRI, 21% subsequently improved eGFR, 67% 
stabilised and 12% progressed. Individuals remaining on TDF or boosted atazanavir 
(ATV/r) 24 months post-CRI had worse eGFR outcomes compared to those 
unexposed  (TDF: 0.47 [0.35-0.63], ATV/r: 0.63 [0.48-0.82]). Individuals off TDF for 
12-24 months (0.75 [0.50-1.13]) or off ATV/r for >12 months (1.17 [0.87-1.57]) had 
similar eGFR outcomes as those unexposed to these ARVs. Older age, 
hypertension, later date of CRI and diabetes were associated with worse eGFR 
outcomes. 
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Conclusion 
Current TDF and ATV/r use after a diagnosis of CRI was associated with worse 
eGFR outcomes. In contrast, TDF and ATV/r discontinuation lead to similar longer-
term eGFR outcomes as in those unexposed suggesting these drug- associated 
eGFR declines may be halted or reversed after their cessation. 
 
Key words  
HIV, eGFR, chronic renal impairment, tenofovir, atazanavir, reversibility 
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Text  
Introduction 
Currently, limited knowledge exists of the longer-term outcomes of renal function 
after the development of chronic renal impairment (CRI) in HIV-positive persons, and 
the relationship with use of antiretroviral (ARV) drugs and other risk factors [1-5]. 
Whilst several commonly used ARVs have been associated with development of 
moderate levels of CRI [6-9], the possibility that ARV-associated CRI may be 
reversible after drug cessation, has not yet been fully investigated. 
Studies of non-ARV drugs with nephrotoxic properties such as aminoglycosides and 
amphotericin B have shown that iatrogenic induced tubular or interstitial renal 
damage is reversible if the damage is recognised early, the causative drug is 
discontinued, low cumulative doses are administered and the patient has few other 
comorbidities that increase the risk of nephrotoxicity [3, 10-14]. However, in contrast 
to most other potentially nephrotoxic drugs, treatment with ARVs is life-long. As a 
consequence high cumulative doses are delivered to the kidneys with a potential for 
accumulating damage to the renal tissue, and risk of more permanent renal 
impairment. Other factors that induce chronic nephron injury leading to renal fibrosis 
(i.e. diabetes and hypertension) are often irreversible, despite initiation of appropriate 
treatment [15]. However, it is plausible that reduced renal function due to ARV-
related CRI, depending on the specific effects and duration of the ARV used, may 
improve or stabilise, whilst CRI associated with traditional renal risk factors may be 
more likely to progress. 
 
Others have investigated associations between the use (and discontinuation) of 
several ARVs, particularly tenofovir (TDF), and the possible reversibility of renal 
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function deterioration. However, the lack of a common definition of reversibility of 
renal function, the small number of cases, limited follow-up and a focus primarily on 
mild and acute renal failure have meant that these studies have provided limited 
insight into this question [1-4, 15-19].Reversibility of renal impairment is a difficult 
endpoint to define as eGFR is known to decline with advancing age [20]. Therefore, 
when assessing longitudinal data on renal function stretching over long follow-up 
periods one cannot expect to see a complete return of eGFR to levels of earlier time-
periods regardless of the intervention. Likewise other comorbidities such as diabetes 
may be progressive in nature making resolution of any ARV-associated eGFR 
decline unlikely despite timely discontinuation [18]. For these reasons, assessments 
of reversibility of renal function should be interpreted with caution, and a focus on 
eGFR improvement, stabilisation or progression may be more informative. 
 
Prior studies from the Data Collection on Adverse events of Anti-HIV Drugs Study 
(D:A:D) have shown increased TDF discontinuation rates already at eGFR<70 
mL/min/1.73m2, thus potentially limiting the value of a confirmed eGFR<60 
mL/min/1.73m2 as a CRI threshold for addressing the question of reversibility of 
ARV-associated renal impairment [8]. This analysis is an extension of earlier work 
from D:A:D suggesting an association between use of certain ARVs and CRI, but in 
which follow-up was too limited to assess eGFR changes after CRI.  
If switching away from ARVs associated with renal impairment results in stabilisation 
or even improvement in eGFR after CRI has developed, this will have major clinical 
implications for future risk stratification in relation to ART initiation and switches.  
The aim of this analysis was therefore to investigate predictors of progression, 
stabilisation or improvement in eGFR after development of CRI.  
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Methods 
The D:A:D study is a prospective cohort collaboration established in 1999 following 
more than 49,000 HIV-1-positive persons in Europe, Australia and the USA; details 
have been published previously [21]. Information on clinical events including end-
stage renal disease and death is collected during routine clinical care, validated 
centrally and regularly monitored. Data on demographic factors, ART, laboratory 
values, cardiovascular risk factors and AIDS events are collected electronically at 
enrolment and every six months thereafter.  
Participants with an eGFR>80 mL/min/1.73m2 after 1/1/2004 (date of systematic 
creatinine collection) actively progressing to CRI (confirmed, >3 months apart, 
eGFR<70 mL/min/1.73m2) with >2 eGFRs in the follow-up period 24-36 months after 
CRI were included in the analysis. Follow-up ended at the earliest of last visit plus 6 
months and 1/2/2016. The requirement of a baseline eGFR>80 mL/min/1.73m2 
ensures an active eGFR decline of >10 mL/min/1.73m2 before CRI, and aimed at 
preventing inclusion of individuals with longstanding CRI with limited potential for 
subsequent eGFR improvement. A 24-36 month follow-up period was included to 
allow sufficient time to establish the subsequent trajectory of renal function.  
 
For each individual, the difference in eGFR between the median of all eGFRs 
measured at 24-36 months after CRI, and the median of the 2 eGFR values defining 
CRI were categorised as eGFR improvement (>+10 mL/min/1.73m2), stabilisation    
(-10 to +10 mL/min/1.73m2) or progression (<-10 mL/min/1.73m2), Supplementary 
Figure 1. 
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The Cockcroft-Gault (CG) equation [22], standardized for body surface area [23], 
was  used to estimate creatinine clearance and as  a surrogate for eGFR in this 
analysis [24]. As several specific cohorts were prohibited from collecting ethnicity 
information the CG was used rather than an equation including ethnicity. 
 
Baseline was defined as the date of CRI (median date of the 2 eGFRs defining CRI), 
and characteristics at baseline were compared between the improvement, 
stabilisation and progression groups using the chi-squared test or the Wilcoxon sign 
rank test.  
 
A polynomial ordinal logistic regression model was used to assess odds of better 
eGFR outcomes after CRI, assuming eGFR improvement is better than stabilisation 
which, in turn, is better than progression. The method assumes that any change in 
odds comparing stable to progressive eGFR is the same as the change in odds 
comparing improved to stable eGFR.  
A multivariable model included the following non-ARV variables, selected a priori and 
measured at baseline; gender, age, hypertension (>150/>100 mmHg or use of 
antihypertensive drugs), prior cardiovascular disease; CVD (case report verified 
myocardial infarction, invasive cardiovascular procedure or stroke, details at 
www.cphiv.dk), diabetes (anti-diabetic treatment or case report verified), HCV (anti-
HCV positive and HCV-RNA positive/unknown), CD4, nadir CD4, , CRI date, eGFR 
at CRI and eGFR slope prior to CRI. The eGFR slope was calculated as the annual 
eGFR change between the first eGFR>80 mL/min/1.73m2 and the eGFR at CRI 
using least squares regression (using all eGFRs available). An eGFR slope of <-10 
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mL/min/1.73m2 defined a faster and >-10 mL/min/1.73m2, a slower eGFR decline 
prior to CRI.  
The model was further adjusted for use of ARVs with a reported association with 
renal impairment: TDF; atazanavir with (ATV/r) or without (ATV) ritonavir; lopinavir 
(LPV/r); other boosted protease inhibitors (PI/r); and abacavir (ABC) [6-9, 25-27]. 
Indinavir use after 2004 was limited and was only included to adjust for potential 
unmeasured confounding.  In all analyses ARV drug use was fitted at time of CRI 
diagnosis plus 24 months to allow for assessment of drug switches at and around the 
time of CRI, Supplementary Figure 1. ARV use was further categorised as never 
exposed, currently on and currently off for ATV, and as never exposed, currently on, 
and currently off (<12 months, 12-24 months and >24 months) for TDF, and never 
exposed, currently on, and currently off (<12 months, >12 months) for all other 
ARVs. These categories were mutually exclusive and chosen to allow sufficient 
numbers within each category for meaningful analysis. Those currently off an 
individual ARV <12-24 months will, by definition, have discontinued use between the 
CRI diagnosis and the time of CRI plus 24 months, while those off the ARV >24 
months, by definition, will have discontinued use before development of CRI. 
All statistical analyses were carried out using SAS version 9.3 (Cary, NC, USA). 
 
Results 
A total of 33,151 persons had an eGFR>80 mL/min/1.73m2 and >3 eGFR 
measurements after 1/1/2004, Figure 1. Of these, 4,456 (13.4%) progressed to CRI 
during prospective follow-up, and 2,006 persons had >2 eGFR measurements 24-36 
months after CRI.  
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Those included in analyses were predominantly white (49.4%) male (76.2%), having 
acquired HIV homosexually (51.2%). The CD4 count closest to baseline (time of 
CRI) was 520 cells/mm3 and median eGFR 65 mL/min/1.73m2. A total of 93.8% were 
on cART, 16.8% had hypertension, 6.3% diabetes for >5 years and 9.2% previous 
CVD. Baseline characteristics in Table 1. 
 
Persons with CRI excluded from the analysis due to lack of eGFR measurements in 
the follow-up period (n=832) or inadequate length of follow-up (n=1618, of whom 144 
persons died) were generally older, had a later baseline date, were less likely to be 
on ART, and have a lower baseline eGFR. Prior exposure to ARVs was similar in 
those excluded to those included (data not shown). Among the 144 persons dying in 
in the follow-up period after CRI the most common individual causes of death were 
non-AIDS defining malignancies (40, 27.8%), AIDS defining illness (19; 13.2%), 
chronic viral hepatitis (17; 11.8%) and unknown causes (16; 11.1%). Only 2 
individuals (1.4%) died of renal related causes. 
 
During follow-up after CRI, 20.7% of included individuals experienced improvement 
in eGFR, 67.0% stabilisation and 12.3% progression. 
 
After adjustment, individuals remaining on TDF at the time of CRI plus 24 months 
follow-up had lower odds of better eGFR outcomes (adjusted odds ratio, aOR, 0.47 
[95% confidence interval, 0.35-0.63]) compared to individuals who had never started 
TDF, Figure 2. Likewise individuals who had been off TDF<12 months at CRI plus 24 
months had lower odds of better eGFR outcomes (0.26 [0.17-0.40]). In contrast, 
individuals off TDF for 12-24 months (0.75 [0.50-1.13]) or >24 months (0.89 [0.61-
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1.31]) had similar odds of better outcomes compared to individuals never exposed to 
TDF. Similar trends were seen for ATV/r except the odds of better eGFR outcomes 
returned to the levels of those who had never started ATV/r <12 months of ATV/r 
discontinuation, Figure 3. Data for unboosted ATV was limited and showed similar 
results to those seen for LPV/r (although not statistically significant), Figure 3. In 
contrast, there was no clear association between use of, or time since 
discontinuation of ABC and other PI/r and outcomes after CRI, Figure 3. 
The results were consistent after follow-up for each of the ARVs was censored for 
any follow-up with concomitant use of the other included ARVs (i.e. follow- up on 
ATV/r use was censored for any TDF use, data not shown). 
 
Older persons had significantly lower odds of better eGFR outcomes (0.58 [0.52-
0.65] per 10 years), but there was no suggestion of a given age at which odds of 
better outcomes started to decrease, Figure 4, Other predictors of worse eGFR 
outcomes were  diabetes >5 years (0.47 [0.32-0.71], hypertension (0.73 [0.56-0.95]) 
and a later date of CRI (0.93 [0,89-0.97). HIV viremia and HCV positivity did not 
significantly impact on eGFR outcomes. While there was no interaction between 
hypertension, diabetes and ARV use (all p>0.05), a significant interaction between 
TDF, age and eGFR outcomes (p=0.0009) was observed, suggesting that the higher 
odds of better outcomes associated with discontinuing TDF were decreased for 
individuals >50 compared to those <50 years. 
 
A large number of sensitivity analyses were carried out to test the robustness of the 
ARV drug associations with eGFR outcomes including looking at outcomes at time of 
CRI, at 12-24 months after CRI or at >36 months after CRI .Results were further 
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unchanged by adjustment for calendar time. Further stratification of exposure to 
ARVs was also investigated, but the confidence intervals became too wide to draw 
clinically relevant conclusions. 
Additional sensitivity analyses tested if the proportional odds assumption was 
reasonable (i.e. that changes in odds comparing eGFR improvement to stabilisation 
was similar to changes comparing eGFR stabilisation to progression).Results were 
tested using a nominal logistic regression model, which showed highly consistent 
results (data not shown). Consistent results were also seen using only two eGFR 
outcomes; improvement/stabilisation versus progression (data not shown).  
Use of confirmed eGFR<60 mL/min/1.73m2 as an alternative CRI definition (with 
progression from an initial eGFR>70 mL/min/1.73m2) did not significantly alter the 
proportions in the eGFR improvement, stabilisation or progression groups, Figure 1. 
The predictors of better eGFR outcomes were likewise largely similar to the primary 
analysis with the exception of  women having better odds of improvement than men 
(1.59 [1.15-2.20]) and being currently on TDF at time of CKD plus 24 months, which 
was no longer significantly associated with a worse eGFR outcome (0.77 [0.50-1.19]) 
as compared to TDF unexposed. Those off TDF for <12 months had similar odds of 
a better eGFR outcome (0.88 [0.52-1.50]), while those off 12-24 months had higher 
odds (1.96 [1.20-3.20]) compared to TDF unexposed. 
 
Finally, a CRI resolution endpoint was investigated; a return to confirmed eGFR>70 
mL/min/1.73m2 at 24-36 months after CRI. Of the 2,006 persons included 470 
(23.4% [21.5-25.3]) experienced CRI resolution, and younger age and earlier date of 
CRI diagnosis were significant predictors (data not shown). The relation between 
TDF use and discontinuation and resolution confirmed the findings of the primary 
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analysis (currently on TDF at CRI plus 24 months 0.43 [0.31-0.60], off <12 months 
0.32 [0.19-0.53], off 12-24 months 0.98 [0.63-1.56] and off >24 months 0.90 [0.59-
1.39]), all compared to TDF unexposed). The relation with the other nephrotoxic 
ARVs did not reach statistical significance, but showed similar findings to those 
shown in Figure 3 (data not shown). 
 
Discussion 
This is the first study to investigate longer-term confirmed eGFR outcomes after 
progression to CRI in HIV-positive persons. Our results suggest that continued use 
of TDF and ATV/r after a CRI diagnosis is associated with worse renal outcomes, 
and that discontinuation of these drugs may in time halt or improve eGFR in 
particular in individuals younger than 50 years. These analyses extend previous 
work from D:A:D demonstrating the association between use of TDF, ATV/r and 
LPV/r and progression to CRI from an initial normal eGFR [8].   
 
ARV use and discontinuation as predictors of eGFR outcomes 
The observation that current use of primarily TDF and ATV/r after CRI, are 
associated with worse eGFR outcomes after CRI are consistent with previous, 
primarily observational, studies linking use of these ARVs with a CRI diagnosis [6-9]. 
The associations with LPV/r and ATV were less clear, possibly due to lack of power, 
but trended towards a worse eGFR outcome, after stopping these ARVs. In contrast, 
there was no suggestion of an association between eGFR outcomes and use of ABC 
or other PI/r. These results suggest that TDF- and ATV/r-associated eGFR declines 
may not represent irreversible renal tissue damage and timely discontinuation may 
independently be beneficial for HIV-positives with declining eGFR. The observation 
that eGFR outcomes were similar in those off ATV/r <12 months and those never 
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exposed to ATV/r, but that this first occurred at >12 months after stopping TDF may 
suggest different underlying biological mechanisms of ARV-related renal impairment. 
As such ATV/r crystaluria/interstitial nephritis may be easier to resolve than TDF-
related tubulopathy, but additional mechanistic studies are warranted.  
It is, of some concern, that the potential to improve/stabilise eGFR seems less strong 
in individuals >50 years, and focus should hence be put on older individual on TDF 
with declining eGFR. Using confirmed eGFR<60 mL/min/1.73m2 to define CRI did 
not reach statistical significance for current TDF use, but showed similar trends of 
increasing odds of better eGFR outcomes with time since TDF discontinuation as in 
the primary analysis. These findings must be interpreted with some caution, as they 
are affected by the common nephrotoxic ARV switches in this eGFR range [8]. The 
eGFR outcomes after ATV/r discontinuation in this exploratory analysis were similar 
to those observed in the primary analysis, with higher odds of better renal outcomes 
after discontinuation, although not reaching statistically significance and limited by 
reduced power and shorter follow-up periods. 
Among the other studies investigating associations between TDF discontinuation 
and renal function, Jose and colleagues likewise showed an overall eGFR 
improvement using median piecewise slope evaluation after switching away from 
TDF [5]. Two safety studies and a small US study found improvement/resolution of 
all TDF-associated renal impairment cases after TDF discontinuation, but suffered 
from several methodological challenges [16, 17, 19]. Other studies have found that 
only certain individuals discontinuing TDF reached their pre-exposure eGFR levels 
suggesting incomplete recovery [1, 4, 6, 18], but the progressive age-related eGFR 
decline is difficult to account for  in these analyses. For ATV, a 2007 FDA study 
found that all individuals with ATV-related urolithiasis regained renal function after 
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stone removal and ATV discontinuation [28], which was supported by the EuroSIDA 
study [6]. Other PI-related urolithiasis are relatively rare, although asymptomatic 
crystalluria may be more prevalent and have, to date, not been assessed in safety 
trials.                                                                                                  
From this and other studies it seems increasingly compelling that a better renal 
outcome is possible after discontinuation of TDF and ATV/r, and possibly other 
nephrotoxic ARVs, after CRI. We were unable to identify a threshold below which 
eGFR improvement or stabilisation was no longer possible despite drug 
discontinuation. It is unknown if such a threshold exists, but it represents an 
essential question to address in the future to enhance identification of when ARVs 
with nephrotoxic potential need to be discontinued to avoid irreversible damage [5]. 
 
Non-ARV predictors of eGFR outcomes  
Age, was as expected, consistently one of the factors most strongly associated with 
a worse eGFR outcome after CRI in this analysis, and is not modifiable.  As also 
expected, hypertension and longer term diabetes were associated with worse eGFR 
outcomes, underlining the importance of optimising blood pressure levels, glycemic 
control, limiting diabetic-related proteinuria. Interestingly a diagnosis of CRI in later 
years was also independently associated with a worse outcome, highlighting the 
need for a more proactive screening and management to prevent CRI.  
We found no association between a fast or slowly declining eGFR slope prior to CRI 
and eGFR outcomes, contrasting  a smaller study where a slowly declining eGFR led 
to worse renal outcomes [1, 31]. No HIV-related factors were associated with better 
eGFR outcomes despite other studies, including earlier D:A:D studies, have seen a 
strong association between eGFR, and current CD4 cell count [8, 32, 33]. This may 
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be due, in part, to the majority of the persons included in this study having well 
controlled HIV and high CD4 counts.  
 
Our results suggest that eGFR improvement after CRI is relatively common, with one 
in five individuals experiencing significant eGFR improvement, and 23% 
experiencing complete resolution of CRI. Likewise, most HIV-positive individuals 
progressing to CRI subsequently stabilised eGFR at moderate levels of renal 
impairment rather than continued to decline. These observations offer reassurance 
for HIV-positive persons and their health care providers as it seems that at least 
some of the excess renal risk among HIV positive persons can be modified with 
appropriate management [32, 33]. Future studies are however needed to assess 
which renal interventions are the most effective for HIV-positive individuals, and at 
which level of renal impairment they should be initiated. 
 
Limitations 
There are some limitations to acknowledge in this analysis. We cannot exclude the 
possibility of selection bias as those excluded from the analysis were more likely to 
have several common renal risk factors, and as a result, we may have 
underestimated the proportion of individuals progressing to CRI. Further a relatively 
large number of individuals were excluded due to insufficient number of eGFR 
measurements or follow-up after the CRI diagnosis, although only two of those 
excluded were known to have died of renal related causes. As a consequence the 
proportion of individuals with eGFR improvement or stabilisation after CRI may be 
overestimated. Exposure to tenofovir alafenamide and cobicistat in D:A:D is to date 
extremely limited and is unlikely to affect our findings. The integrase inhibitor 
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dolutegravir inhibits renal creatinine secretion with artefactual eGFR declines, but 
this is unlikely to explain our findings as all individuals in this analysis had an eGFR 
decline >10 mL/min/1.73m2. Finally, unmeasured confounding cannot be ruled out 
due to the lack of urinary markers, biopsy findings, family history and the use of other 
nephrotoxic non-ARV drugs. Our main conclusions were however tested in a number 
of sensitivity analyses with consistent results, including modifying the CRI and eGFR 
outcomes; fitting ARV exposure at different time-points and after censoring follow-up 
time for concomitantly used ARVs. 
 
Conclusions 
Even after progression to a diagnosis of CRI, subsequent longer-term improvements 
in renal function are relatively common among HIV-positive persons, with the 
majority stabilising and only few persons experiencing continued decline in eGFR 
over time. Older age, hypertension, longer-term diabetes, later date of CRI diagnosis 
and use of TDF and ATV/r were associated with lower odds of better eGFR 
outcomes after CRI. Persons who stopped TDF and ATV/r had similar eGFR 
outcomes compared to those who had never started these ARVs, suggesting that 
ARV-associated eGFR decline may be halted or reversed with timely drug cessation. 
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Figure 1. Flowchart of inclusion into the primary and sensitivity analyses 
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Table 1. Characteristics at time of CRI1  
 
 
 
 
 
 
 
 
 
1. CRI = baseline; date of confirmation eGFR measurement, 2 Improvement in eGFR defined as 
(>+10 mL/min/1.73m2), stabilisation (-10 to +10 mL/min/1.73m2) and progression (<-10 
mL/min/1.73m2). 3. men having sex with men, 4. Defined as the annual eGFR change between the 
first eGFR>80 mL/min/1.73m2 and the eGFR at CRI; <-10 mL/min/1.73m2 defined a faster and >-10 
mL/min/1.73m2 a slower eGFR decline 
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Figure 2. 
Adjusted Odds Ratios of Better eGFR Outcomes After  
Chronic Renal Impairment according to Use of TDF  
 
 
 
 
 
 
 
 
 
 
 
Adjusted for gender, age, nadir CD4, baseline CD4 count, CRI date, eGFR at CRI, eGFR slope prior 
to CRI, HCV status, diabetes, hypertension, prior cardiovascular disease and use of TDF, ATV/r, 
ATV, LPV/r, other PI/r, IDV and ABC at CRI plus 24 months.   
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Figure 3. 
 Adjusted Odds Ratios of Better eGFR Outcomes After Chronic Renal 
Impairment According to Use of Other ARVs 
 
 
 
 
 
 
 
 
 
Adjusted for gender, age, nadir CD4, baseline CD4 count, CRI date, eGFR at CRI, eGFR slope prior 
to CRI, HCV status, diabetes, hypertension, prior cardiovascular disease and use of TDF, ATV/r, 
ATV, LPV/r, other PI/r, IDV and ABC at CRI plus 24 months. 
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Figure 4. 
Associations Between Non-ARV Factors  
and Better Renal Outcomes after Chronic Renal Impairment 
 
 
 
 
 
 
 
 
Adjusted for gender, age, nadir CD4, baseline CD4 count, CRI date, eGFR at CRI, eGFR slope prior 
to CRI, HCV status, diabetes, hypertension, prior cardiovascular disease and use of TDF, ATV/r, 
ATV, LPV/r, other PI/r, IDV and ABC at CRI plus 24 months. 
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Supplementary Figure 1. 
Methods 
 
